Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0032463 (
polycythemia vera
)
3,374
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Five patients with myeloproliferative disorders and paraprotein are reported. The diseases included acute myelomonocytic leukemia, chronic myeloid leukemia, sideroblastic anemia with excess of blasts,
polycythemia vera
and myelofibrosis. In four cases, the paraprotein was of the IgG k type and in one, IgM k. No evidence of multiple myeloma or excessive
plasmacytosis
was noted. The literature records 19 other myeloid disorders with this unusual association. Although the pathogenesis remains unclear, three possible explanations are suggested: disturbance of the pluripotent stem cell resulting in a combined myeloplasmatic disorder, coexistence of two diseases, or a fortuitous association.
...
PMID:Myeloproliferative disorders and nonmyelomatous paraprotein. A study of five patients and review of the literature. 394 87
The human erythropoietin receptor (EpoR) gene has been cloned and characterized. Very few EpoR genetic abnormalities have been reported so far.
Polycythemia vera
(PV) is characterized by low/normal serum erythropoietin (Epo) levels with proposed Epo hypersensitivity. Myelodysplastic syndromes (MDS) are characterized by refractory anemia with variable serum Epo levels. Several reports have suggested EpoR abnormalities in both types of stem cell disorders. We analyzed DNA obtained from peripheral blood mononuclear cells of seven healthy controls, 20 patients with myeloproliferative disorders (MPD, 11 patients with PV, five agnogenic myeloid metaplasia with myelofibrosis, four essential thrombocytosis) and eight patients with refractory anemia with ringed sideroblasts (RARS), an MDS variant. The DNA was digested with four restriction enzymes (BamHI, Bgl II, Sacl and HindIII), followed by Southern blot, using a 32P radiolabeled probe, containing 1.5 kb of the human EpoR cDNA. All 20 MPD patients and seven out of the eight MDS patients demonstrated a restriction pattern which was identical to the seven normal controls, as well as to the erythroid cell line K562, and also consistent with the expected restriction map, for all four enzymes tested. One RARS patient had a normal pattern with three enzymes but a different one with HindIII. The HindIII 12 kb large band was replaced by a faint 12 kb band and a new (about 9 kb) band appeared. The EpoR restriction map and the normal pattern obtained with the other three enzymes suggest that this patient has a 3 kb upstream deletion in one allelic EpoR gene. The same molecular pattern was detected in the patient's sister, who suffers from anemia with mild bone marrow (BM) dyserythropoiesis and
plasmacytosis
. Northern blot analysis showed that the patient's BM RNA carried normal EpoR message. This familial pattern may represent polymorphism. However, the patient's very high serum Epo level, her resistance to treatment with recombinant Epo, and the abnormally low growth rate of in vitro erythroid cultures, suggesting poor response to Epo in this MDS patient as well as the hematological abnormalities in her sister, support the speculation that the different EpoR gene might serve as a genetic predisposing marker and potentially could be involved (probably via post-transcriptional mechanisms and by an interaction with other factors or cytokines) in the pathogenesis. Our data suggest that the EpoR is intact in MPD and in most patients with RARS. One RARS patient had a familial different genetic structure, which could represent polymorphism. However, we can speculate also that it might be involved in the pathogenesis of the disease.
...
PMID:Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. 870 17
Differentiation of an elevated hemoglobin/hematocrit level warrants not only the determination of relevant laboratory values, including erythropoietin, but also an elaborate evaluation of bone marrow histopathology. Particularly in the initial stages of
polycythemia vera
(PV), when not all stringent clinical criteria are completely fulfilled, a more refined analysis of morphological features helps to distinguish autonomous (PV) from spurious or secondary erythrocytosis - polyglobuly (PG). PV is characterized by a panmyelosis, i.e., a trilinear proliferation of all cell lineages, whereas in PG erythropoiesis predominates. Megakaryopoiesis exerts a significant impact on differentiation, because in PV there is a conspicuous grouping associated with a strikingly expressed pleomorphous appearance. This peculiar feature implicates assemblies of small- to medium-sized megakaryocytes lying adjacent to giant cells with extensively lobulated, staghorn-like nuclei. A further discriminating parameter is presented by the interstitial lesions frequently occurring in PG. These, according to the usually underlying inflammatory cause (chronic bronchitis-recurrent bronchopneumonias), include iron-laden macrophages, a prominent perivascular
plasmacytosis
, phagocytosis of cell debris by histiocytic reticular cells and often an in- crease in the number of eosinophils. Comparable findings are not, or only to a minor ex-tent, detectable in PV. In conclusion, by regarding hematopoiesis and the myeloid stroma initial stages of PV may be definitively distinguished from PG.
...
PMID:[ Polyglobuly versus polycythemia vera]. 1066 66
To determine parameters of distinctive value in
polycythemia rubra vera
(PV) versus secondary polycythemias (SP), a clinicopathological study was performed on 199 patients. These presented with a borderline to marked elevation of the hemoglobin level (> 18 g/dl in men and > 16 g/dl in women). Evaluations of clinical features and bone marrow histopathology were carried out independently. According to the results derived from laboratory data and representative pretreatment trephine biopsies, three groups of patients emerged: group I presenting with the concordant clinical and morphological findings of early to manifest PV (136 patients), group II consisting of 55 patients with the congruent signs and symptoms of SP mostly caused by various chronic bronchopulmonal disorders, and finally eight patients (group III) with divergent findings. Between group I and II patients (PV versus SP), a number of clinical parameters proved to be significantly different. With the exception, of the red cell mass, platelet count, leukocyte alkaline phosphatase, LDH, spleen size, and the erythropoietin level had a significantly discriminating impact. Morphological features of distinctive value consisted of a set of specific lesions. Contrasting SP with an only borderline to slight increase in cellularity associated with a moderate enlargement of the erythroblastic islets, PV was always characterized by a significant increase in hematopoiesis, revealing a trilinear proliferation (panmyelosis). Megakaryopoiesis was strikingly different in PV as compared to SP by displaying clustering and a pleomorphous appearance. i.e., very small and giant megakaryocytes with staghorn-like nuclei were neighboring each other. Moreover, conspicuous alterations of the interstitial compartment were recognizable in SP. These consisted of deposits of cell debris in histiocytic reticular cells, iron-laden macrophages, and a
plasmacytosis
, implying an inflammatory reaction. These changes were only very rarely observed in PV, as opposed to a minimal to slight increase in reticulin fibers in about 12% of patients. In conclusion, a more elaborate evaluation of bone marrow features resulted in a set of diagnostic criteria with discriminating capacity that should be considered in prospective clinical trials.
...
PMID:Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. 1126 21
The criteria of the
Polycythemia Vera
Study Group (PVSG), although acknowledged as the gold standard to establish the diagnosis of
polycythemia vera
(PV), do not regard bone marrow (BM) histopathology. Arguments include the existence of sufficient objective markers of disease and the lack of independently performed morphological studies or standardized criteria. The aim of this review is to evaluate morphological characteristics of erythrocytosis and to determine whether distinctive patterns of histopathology exist. A review of the pertinent literature and evaluation of 334 patients from our files with a borderline to marked increase in hemoglobin was performed. In extension to former descriptions of BM features by the PVSG, a tri-lineage myeloproliferation (panmyelosis) with a pleomorphous appearance of megakaryopoiesis revealed that, besides increase in size, there was a lack of gross cytological anomalies. Differentiation from secondary polycythemia (SP) was accomplished by regarding these features and the conspicuously expressed stromal changes (
plasmacytosis
, eosinophils, cell debris and iron deposits). In about 96% of this cohort a clear-cut separation from SP was achieved, even in the initial (latent) stages. When accompanied by an elevated platelet count, these precursor stages may clinically mimick essential thrombocythemia because they are not recognized by the conventional criteria. Advanced stages (spent phases) of PV were consistent with an increased left-shifted granulocytic proliferation, accompanied by reduction of erythroid precursors and progressive myelofibrosis (post-polycythemic myeloid metaplasia). Finally, an increase in dysplastic changes and immaturity signalled a transition into blastic crisis. In conclusion, PV is characterized by a distinctive pattern of histopathology that has been gained in an independent and blind fashion and therefore, dissolves arguments about failing specificity.
...
PMID:Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). 1557 48
Controversy continues to persist about the role of histopathology regarding diagnosis of
polycythemia vera
(PV). For this reason, a clinicopathological study was performed on 334 patients presenting with a sustained borderline to marked erythrocytosis (hemoglobin >17 g/dl in men and >15 g/dl in women). The aim was to elucidate the discriminating impact of bone marrow biopsy examinations in an independent fashion from laboratory parameters. According to morphological findings based on a semiquantitative evaluation of standardized features, cellularity, megakaryocytes (quantity, size, pleomorphous aspect, clustering, nuclear lobulation), eosinophils, cellular debris, perivascular
plasmacytosis
and iron-laden macrophages exerted a distinctive value. Comparison with clinical data and follow-up revealed that in only 13 patients (4%), histopathology failed to differentiate clearly between PV (208 patients) and secondary polycythemias (113 patients). In conclusion, certain sets of morphological parameters allow a distinction between autonomous and reactive polycythemias and therefore enhance significantly diagnostic validity.
...
PMID:Bone marrow features of diagnostic impact in erythrocytosis. 1580 15
The diagnostic criteria of the
Polycythemia Vera
Study Group (PVSG) do not include bone marrow (BM) examinations. The aim of this review is to elucidate whether distinctive patterns of histopathology exist which discriminate reactive (secondary polycythemia) from autonomous (
polycythemia vera
) erythrocytosis. When accompanied by an elevated platelet count, the initial stages of PV may clinically mimic essential thrombocythemia because they are not recognized by the conventional diagnostic criteria. Our data are derived from previous studies and evaluations of 362 patients with a borderline to marked increase in hemoglobin. PV revealed a trilineage myeloproliferation (panmyelosis) with a pleomorphous appearance (ie, differences in size) of loosely clustered megakaryocytes that failed to show gross cytological anomalies. Distinction from SP was accomplished by regarding megakaryopoiesis and the stromal changes (perivascular
plasmacytosis
, eosinophils, cell debris, and iron deposits). Discriminant analysis of standardized BM features, based on semiquantitative evaluation, yielded a sensitivity of 96% concerning the clear-cut separation of PV from SP.
...
PMID:Diagnosis of polycythemia vera based on bone marrow pathology. 1586 75
The diagnostic criteria of the
Polycythemia Vera
Study Group do not consider bone marrow histopathology, nor do they recognize the dynamics of
polycythemia vera
(PV). Precursor stages, when accompanied by an elevated platelet count, may clinically mimic essential thrombocythemia. Significantly extending former descriptions of bone marrow features, a trilineage myeloproliferation (panmyelosis) with a pleomorphous appearance (differences in size) of megakaryopoiesis is a characteristic histopathologic finding in PV. Differentiation from secondary polycythemia is accomplished by also considering the conspicuously expressed stromal changes (perivascular
plasmacytosis
, eosinophils, cell debris, and iron deposits). A clear-cut discrimination is possible, even in the initial (latent) stages of PV, which do not fulfill all the conventional diagnostic criteria. Advanced stages (spent phases) of PV show an increased left-shifted granulocytic proliferation accompanied by reduction of erythroid precursors and progressive myelofibrosis (postpolycythemic myeloid metaplasia). Finally, an increase in dysplastic changes and immaturity of cell lineages signals a transition into blastic crisis.
...
PMID:Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis? 2042 37